Bruce J. McCreedy
SLRXAbout Bruce J. McCreedy
Bruce J. McCreedy, Ph.D., age 66, has served on Salarius Pharmaceuticals’ Board since July 2019; he holds a B.S. in Medical Microbiology and a Ph.D. in Microbiology & Immunology from Wake Forest University School of Medicine, with extensive biotech leadership in cell therapy and immuno-oncology . He is currently deemed an independent director under Nasdaq and SEC rules .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| ONK Therapeutics, Inc. | Chief Scientific Officer | Dec 1, 2022 – present | CSO leadership in oncology therapeutics |
| Myeloid Therapeutics, Inc. | Chief Scientific Officer | Apr 2021 – Nov 2022 | CSO role in immuno-oncology |
| Salarius Pharmaceuticals | Interim Chief Science Officer | Jan 2020 – Mar 30, 2021 | Supported R&D transition; interim executive |
| Precision Biosciences, Inc. | SVP, Cell Therapy | 2015 – 2020 | Cell therapy development leadership |
| NexImmune, Inc. | EVP R&D & Chief Development Officer | Apr 2011 – Aug 2015 | Led R&D and development strategy |
| PharmaNav, LLC | Managing Partner | 2008 – 2011 | Biotech advisory/management |
| Metabolon, Inc. | VP Strategic & Clinical Development | 2006 – 2008 | Clinical development strategy |
| Fulcrum Pharma Developments, Inc. | President, CEO, and Director | 2002 – 2006 | Led company; later acquired by ICON plc |
| Triangle Pharmaceuticals, Inc. | Vice President | Pre-2002 | Executive role; company acquired by Gilead |
| Therapyedge, Inc. | CEO | Pre-2002 | Healthcare & information services |
| LabCorp / Roche Biomedical Labs | Associate Vice President | Pre-2002 | Clinical lab network leadership |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| ONK Therapeutics, Inc. | Chief Scientific Officer | Dec 1, 2022 – present | Current external operating role |
| Myeloid Therapeutics, Inc. | Chief Scientific Officer | Apr 2021 – Nov 2022 | Prior CSO role |
| Fulcrum Pharma Developments, Inc. | Director | 2002 – 2006 | Board role at predecessor company |
Board Governance
- Committee assignments: Member, Nominating & Corporate Governance Committee; not Chair (Chair is Tess Burleson) .
- Independence: Board determined McCreedy is “independent” under SEC and Nasdaq rules .
- Tenure/class: Class II director; term expires at the 2026 annual meeting .
- Attendance and engagement: In 2024 the Board met five times; each director attended at least 75% of aggregate Board and committee meetings; Nominating & Corporate Governance Committee held zero meetings (Audit 4; Compensation 2) .
- Board leadership and risk oversight: Board-level oversight, with Audit monitoring financial risk and related-person transactions; Compensation monitors plan compliance .
- Insider trading policy: Prohibits hedging and short sales by directors, officers, and employees; policy filed as Exhibit 19.1 to FY2024 10-K .
Fixed Compensation
| Component (2024) | Amount | Source |
|---|---|---|
| Fees Earned or Paid in Cash | $37,000 | |
| Stock Options (grant-date fair value) | $9,944 | |
| Total | $46,944 |
- Cash retainer policy changes effective April 1, 2024: Board retainer $30,000; Chair of Board +$20,000; Audit Chair +$10,000; Audit members +$3,500; no cash retainers for Compensation or Nominating Committee roles .
- Outstanding equity awards (as of Dec 31, 2024): 194 options; 12 restricted shares of common stock .
Performance Compensation
| Item | Disclosure | Source |
|---|---|---|
| Performance metrics tied to director pay | None disclosed; director compensation comprised of cash retainers and equity awards | |
| Option strike price / expiration / vesting | Not disclosed | |
| RSU/PSU performance conditions | Not disclosed |
Other Directorships & Interlocks
| Company | Public/Private | Role | Tenure |
|---|---|---|---|
| Fulcrum Pharma Developments, Inc. | Not specified | Director | 2002 – 2006 |
- No current public company directorships disclosed for McCreedy beyond SLRX .
- No disclosed interlocks with competitors/suppliers/customers involving McCreedy .
Expertise & Qualifications
- Deep biotechnology and cell therapy expertise across CSO and senior development roles; board cites his experience as a key qualification to contribute strategic insights .
- Scientific credentials: Ph.D. in Microbiology & Immunology; B.S. in Medical Microbiology (Wake Forest) .
Equity Ownership
| As of Oct 24, 2025 | Shares | Notes |
|---|---|---|
| Common shares owned | 12 | Direct holdings |
| Options exercisable within 60 days | 194 | Included in beneficial ownership |
| Total beneficially owned | 206 | SEC beneficial ownership definition |
| Percent of shares outstanding | <1% | 1,051,782 shares outstanding basis |
| Shares pledged | Not disclosed | |
| Ownership guidelines | Not disclosed |
Governance Assessment
- Positive: Independent status under Nasdaq/SEC and science-led background enhances board oversight on R&D strategy .
- Positive: Anti-hedging and short-sale prohibitions align interests and reduce misalignment risks .
- Watch item: Nominating & Corporate Governance Committee held zero meetings in 2024, potentially signaling low cadence of governance refresh or evaluation activity; context may be limited board changes that year .
- Alignment: 2024 compensation mix is majority cash with modest equity options ($37,000 cash vs. $9,944 equity), providing some long-term alignment but with de minimis ownership as of 2025 (<1%) .
- Conflicts: No related-party transactions disclosed involving McCreedy; separate related-person exposure noted for another director (DeuteRx) but none for McCreedy .
RED FLAGS (to monitor): Low committee activity in Nominating & Governance in 2024; limited personal share ownership relative to outstanding shares, which may dampen perceived “skin-in-the-game” despite option exposure .